However, no studies have addressed whether the anti-β2GPI/HLA-DR antibody can be a significant risk for other adverse obstetric outcomes, including fetal growth restriction (FGR), hypertensive disorders of pregnancy (HDP), and preterm delivery (PD). The gene discussed is APOH; the disease is fetal growth restriction.